The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.

In preferred embodiments the invention is directed to ocular compositions for the treatment of dry eye, methods for making such compositions, and suites comprising a plurality of different ocular compositions each having a defined composition. In preferred examples, the invention is directed to compositions comprising at least one natural oil, wherein a first member of the suite of compositions is effective in treating dry in in a first patient having a particular set of symptoms and a different second member of the suite of compositions is effective in treating dry in in a second patient having a different set of symptoms. The invention is also directed to methods of making and using the compositions, and to skin care compositions for use around the eye, such as the upper and lower eyelids having a lubricating, non-irritating base composition comprising at least one natural oil.

Optical sensors, systems and methods of use thereof are provided. Aspects of the subject systems include a sensor having a sensing surface and a configuration that directs a first optical signal to interact with the sensing surface at a first incident angle, and directs a second optical signal to interact with the sensing surface at a second incident angle. The subject sensors, systems and methods find use, e.g., in the diagnosis of dry eye disease.

The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.

The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.

Compositions, methods, and kits are provided for diagnosing and treating uveitis. In particular, biomarkers have been identified that can be used to distinguish infectious uveitis from noninfectious uveitis, and further discriminate among bacterial, viral, and fungal uveitis. These biomarkers can be used alone or in combination with one or more additional biomarkers or relevant clinical parameters in prognosis, diagnosis, or monitoring treatment of uveitis.

A method for rapid detection of dry eye syndrome includes collecting a first tear fluid from healthy participant and a second tear fluid from patient with eye dryness; isolating EV samples from the first tear fluid; acquiring a first fingerprint diagram of proteomes of the EV samples from the first tear fluid, the first fingerprint diagram comprises a plurality of first discriminant peaks; isolating EV samples from the second tear fluid; acquiring a second fingerprint diagram of proteomes of the EV samples from the second tear fluid, the second fingerprint diagram comprises a plurality of second discriminant peaks; and comparing the first discriminant peaks and the second discriminant peaks to determine whether the patient has the DES. This is a fast and precise method for detecting the DES of the participant.

The present invention relates to: a composition for differentially diagnosing Acanthamoeba keratitis, the composition comprising chorismate mutase antibodies; and an Acanthamoeba keratitis diagnosis kit using same. The composition comprising chorismate mutase antibodies according to the present invention causes an antigen-antibody reaction only specific to a chorismate mutase protein secreted from Acanthamoeba, thus making it possible to diagnose Acanthamoeba keratitis and differentiate the cause of Acanthamoeba keratitis more rapidly and accurately than existing methods for diagnosing Acanthamoeba keratitis. The composition is expected to be widely applicable to the production of Acanthamoeba keratitis diagnosis kits, therapeutic agents, contact lens disinfecting agents, and the like using the composition.

Disclosed are formulations and procedures to improve the accuracy of nonanimal tests. Disclosed procedures involve both the direct application of the substance to be tested to the excised eye or other suitable test matrix, such as a differentiated tissue, and the application of an aqueous layer to the apical surface and then the addition of the substance to be tested as an overlay to the aqueous layer for a period of time so as to allow metabolism of the substance to be tested by the eye or test matrix, but not so long as to result in nonirritant or nontoxic test substance resulting in a FP result.

The present invention provides a method, wherein the method classifies a subject as suffering from dry eye, the method consisting of: a. obtaining demographic data, consisting of the age and gender of the subject; b. obtaining a tear sample from the patient, and determining the level of human serum albumin; c. from the determined level of human serum albumin, assigning a score for the determined amount of human serum albumin; and d. from the assigned score, calculating a cutoff probability score, according to the following equation:

[00001]$\frac{\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}{1+\exp \left(-0.6491-1.1142*\mathrm{Albumin}\right)}$

wherein the subject has dry eye, if the calculated cutoff probability score is from 50% to 60%.